PMID- 31114240
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1178-6930 (Print)
IS  - 1178-6930 (Electronic)
IS  - 1178-6930 (Linking)
VI  - 12
DP  - 2019
TI  - LncRNA MIR100HG promotes cancer cell proliferation, migration and invasion in 
      laryngeal squamous cell carcinoma through the downregulation of miR-204-5p.
PG  - 2967-2973
LID - 10.2147/OTT.S202528 [doi]
AB  - Purpose: LncRNA MIR100HG promotes several types of malignancies, while its 
      involvement in other human diseases is unknown. Patients and methods: Our study 
      included 70 patients with LSCC who were diagnosed and treated in the First 
      Affiliated Hospital and College of Clinical Medicine of Henan University of 
      Science and Technology from January 2016 to July 2018. qRT-PCR, cell 
      transfection, in vitro cell proliferation assay, cell migration and invasion 
      assay were applied for the research. Results: In the present study we found that 
      MIR100HG was upregulated, while miR-204-5p was downregulated in tumor tissues 
      than in adjacent healthy tissues of laryngeal squamous cell carcinoma (LSCC) 
      patients. Expression of MIR100HG was significantly affected by AJCC stage. A 
      significant and inverse correlation between MIR100HG and miR-204-5p was found in 
      tumor tissues but not in adjacent healthy tissues of LSCC patients. 
      Overexpression of MIR100HG resulted in the downregulation of miR-204-5p in LSCC 
      cells, while miR-204-5p overexpression failed to significantly affect MIR100HG 
      expression. Overexpression of MIR100HG led to promoted, while miR-204-5p, 
      overexpression led to inhibited proliferation, migration and invasion of LSCC 
      cells. In addition, miR-204-5p overexpression attenuated the enhancing effects of 
      MIR100HG overexpression on cancer cell proliferation, migration and invasion. 
      Conclusion: Therefore, lncRNA MIR100HG promoted cancer cell proliferation, 
      migration and invasion in LSCC possibly through the downregulation of miR-204-5p.
FAU - Huang, Yongyang
AU  - Huang Y
AD  - Department of ENT, The First Affiliated Hospital, and College of Clinical 
      Medicine of Henan University of Science and Technology, Luoyang, Henan 471000, 
      People's Republic of China.
FAU - Zhang, Chao
AU  - Zhang C
AD  - Department of ENT, The First Affiliated Hospital, and College of Clinical 
      Medicine of Henan University of Science and Technology, Luoyang, Henan 471000, 
      People's Republic of China.
FAU - Zhou, Yanhui
AU  - Zhou Y
AD  - Department of ENT, The First Affiliated Hospital, and College of Clinical 
      Medicine of Henan University of Science and Technology, Luoyang, Henan 471000, 
      People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20190417
PL  - New Zealand
TA  - Onco Targets Ther
JT  - OncoTargets and therapy
JID - 101514322
PMC - PMC6489621
OTO - NOTNLM
OT  - laryngeal squamous cell carcinoma
OT  - lncRNA MIR100HG
OT  - miR-204-5p
COIS- The authors report no conflicts of interest in this work.
EDAT- 2019/05/23 06:00
MHDA- 2019/05/23 06:01
PMCR- 2019/04/17
CRDT- 2019/05/23 06:00
PHST- 2019/01/22 00:00 [received]
PHST- 2019/03/07 00:00 [accepted]
PHST- 2019/05/23 06:00 [entrez]
PHST- 2019/05/23 06:00 [pubmed]
PHST- 2019/05/23 06:01 [medline]
PHST- 2019/04/17 00:00 [pmc-release]
AID - 202528 [pii]
AID - 10.2147/OTT.S202528 [doi]
PST - epublish
SO  - Onco Targets Ther. 2019 Apr 17;12:2967-2973. doi: 10.2147/OTT.S202528. 
      eCollection 2019.